Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated August 08, 2016 titled "Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA". Buy Sun Pharmaceutical Industries, target Rs 890: Swati Hotkar
Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 890 and a stop loss at Rs 830
Sun Pharma gets USFDA nod for Glumetza tablets
Sun Pharma says the commercial launch of the Glumetza tablets in the US is expected over the next few weeks Sun Pharma announces US FDA approval for generic Glumetza
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated August 02, 2016 titled "Sun Pharma announces US FDA approval for generic Glumetza." Sun Pharma to announce first quarter results on August 12, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated August 01, 2016 titled "Sun Pharma to announce first quarter results on August 12, 2016". Q1 results on August 12, 2016
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 12, 2016, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2016 (Q1).Further, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from August 03, 2016 to August 17, 2016 (both days inclusive).
Mumbai court directs Sun Pharma to pay pending wages to 86 employees
Mumbai court holds Sun Pharma responsible for committing unfair labour practices after its merger with Ranbaxy Laboratories in March 2015
Sun Pharma enters licensing pact with Almirall to market psoriasis drug in Europe
Under the terms of the licence agreement, Almirall will pay Sun Pharma an initial payment of $50 million Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated July 27, 2016 titled "Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis." Updates
Sun Pharmaceutical Industries Ltd has informed BSE that the Company on July 27, 2016 signed an agreement with RPG Life Sciences Ltd to divest seven prescription brands in India, owned by Sun Pharmaceutical Industries Limited and its subsidiary, for a consideration of INR 41 Crores.The 7 (seven) divested brands include brands used for treatment of respiratory-track infections, urological disorders, cardiovascular diseases and brands in health supplements segment....